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Delay in Response to Acute Myocardial Infarction
We thank Drs. Wielgosz and Nolan for their recent thoughtful editorial1 commenting on our study.2 Overall, we accept the majority of their comments. It is certainly true that many important clinical questions remain about delay in seeking treatment for acute myocardial infarction patients.
In many ways, our study is a pilot investigation plagued by the problems inherent in any retrospective analysis of relatively small sample size. A multicomponent, multivariate, prospective research design would be the ideal approach to examine delay, and we hope to be able to conduct such a study soon. Future studies replicating our findings are warranted before widespread implementation of intervention programs. However, we are not as reluctant as Drs. Wielgosz and Nolan in advocating the use of interventions with specific groups based on research findings to date while we await results of future studies. A consideration of interactions of personality with social and situational influences is an excellent suggestion that probably would provide a more comprehensive understanding of treatment-seeking behavior. However, the search for a comprehensive understanding of delay should not detain us from attending as soon as possible to the pragmatic requirements of clinical care. We do not suggest that personality traits are sufficient to account for delay, but we do suggest that knowledge of personality factors can offer potential predictive usefulness.
Wielgosz and Nolan pose an interesting question in wondering whether highly emotionally aware individuals might be distracted by their symptoms and thus also be less likely to seek treatment rapidly. Although high levels of emotional arousal have been correlated with delay, results of our study did not support this. The tripartite classification of emotional awareness indicated that those highly aware individuals had the shortest median delay (3.8 hours) compared with those with intermediate (5.0 hours) or low levels of awareness (12.8 hours). In addition, our article contains an ANCOVA that removes the influence of symptom severity from the test of the relation between emotional awareness and treatment-seeking delay. In our sample, at any given level of symptom severity, those who scored high on emotional awareness tended to take less time to seek treatment.
Although we agree that physicians should continue educating patients about symptom recognition and importance of a prompt response to symptoms, we also believe that this has failed as a solo strategy. Our results reflected the findings of other studies in suggesting that factors such as prior cardiac history and prior myocardial infarction do not appear to shorten delay times for subsequent cardiac events. The work of Ho and colleagues4 and Mitic and Perkins5 also illustrate difficulties inherent in a simple fact-based message.
We believe that cardiac care might well be improved by routine use of psychometric screening instruments such as those used in our study. It would seem reasonable to develop intervention programs for those who demonstrate reduced awareness of somatic and emotional sensations, at least for those who have already delayed excessively in responding to symptoms of a myocardial infarction and are at risk of recurrent events. Both emotional and somatic awareness are of interest, not only because of our results but also because two other studies indicate an independent association with severity of coronary artery disease.67 Although space precludes a current review of research to date, additional psychological factors that have been implicated as pertinent to planning and care of the cardiac patient include social support, anger, depression, and anxiety. While the mechanisms relating these behavioral phenomena to disease onset and progression continue to be debated,8-10 their relevance to clinical course is increasingly well established. This error prompted us to recalculate the QT, values for the entire group, and find that all the listed values were incorrect.
Using the Bazett formula, one patient had a QTc between 440 and 460 msec, four had a QTc between 460 and 500 msec, and two were greater than 500 msec (520 msec and 600 msec). The two patients with a QT, over 500 msec had sinus tachycardia, which probably contributed to the prolonged QTC.3
The authors defined a prolonged QT and QT, of 440 and 460 msec, respectively. The value of the QT (440 msec) as an upper limit of normal is generally accepted except by some authors who believe that this value is based on insufficient evidence.3 A similar study, which the authors did not cite, was reported in 1984 by Grenadier et al,4 who analyzed nine patients with polymorphous ventricular tachycardia in acute myocardial infarction. The results of Grenadier's study were similar to those of Wolfe and coworkers, demonstrating poor prognosis of patients with polymorphous ventricular tachycardia associated with acute myocardial infarction. In the Grenadier et al study, six patients died during hospitalization, and the remaining three died within 6 months. These authors also showed that in three of four patients, verapamil suppressed the tachyarrhythmia without influencing the long-term prognosis.
Eric H. Stem, MD Assistant Chief, Cardiology Section Bronx Veterans Affairs Medical Center Nifedipine Reduces the Incidence of Myocardial Infarction and Transient Ischemia in Patients Undergoing Coronary Bypass Grafting Seitelberger et al's' recent claim that "nifedipine reduces the incidence of myocardial infarction in patients undergoing coronary bypass grafting" is in error. The authors used the wrong statistical test to analyze their data. When one or more of the expected cell sizes in a 2 x 2 table contain less than five observations, the appropriate statistical test is Fisher's exact test, not the X2.2,3 Half (two of four) of the cells in their 2 x 2 table of myocardial infarction by treatment had expected values of less than 5. Simply looking at the data on the risk of infarction (two of 53 patients in the nifedipine group compared with six of 50 patients in the nitroglycerin group) should have made the authors' claim of statistical significance suspect; in fact, Fisher's exact test yields a probability value of 0.15, which is substantially different from the probability value of less than 0.001 reported in the abstract. In any case, our calculation of the X2 statistic would result in a continuity corrected X2 value of 1.42 (p=0.23).
The authors have also miscalculated the statistical significance of the difference in the incidence of myocardial ischemia in the two groups (three of 53 patients in the nifedipine group compared with nine of 50 in the nitroglycerin group). They reported a probability value of less than 0.001; our calculation of the continuity corrected X 2 statistic yields a value of 2.70 (p=0.10).
We suggest that the authors be given the opportunity to correct these mistakes in their analysis and to alter their conclusions about the efficacy of nifedipine compared with nitroglycerin.
Another area of concern is that in this study, none of the patients had their usual doses of cardiac medications on the morning of surgery. One wonders if the results would be similar if cardiac medications were continued till the morning of surgery, which is the more standard way of perioperative practice. Withdrawal of pB-blocking agent, for example, is known to increase the incidence of ischemia, arrhythmias, and infarction. 4 Finally 
